HLA Variation and SARS-CoV-2 Specific Antibody Response
- PMID: 37112884
- PMCID: PMC10143129
- DOI: 10.3390/v15040906
HLA Variation and SARS-CoV-2 Specific Antibody Response
Abstract
Differences in SARS-CoV-2-specific immune responses have been observed between individuals following natural infection or vaccination. In addition to already known factors, such as age, sex, COVID-19 severity, comorbidity, vaccination status, hybrid immunity, and duration of infection, inter-individual variations in SARS-CoV-2 immune responses may, in part, be explained by structural differences brought about by genetic variation in the human leukocyte antigen (HLA) molecules responsible for the presentation of SARS-CoV-2 antigens to T effector cells. While dendritic cells present peptides with HLA class I molecules to CD8+ T cells to induce cytotoxic T lymphocyte responses (CTLs), they present peptides with HLA class II molecules to T follicular helper cells to induce B cell differentiation followed by memory B cell and plasma cell maturation. Plasma cells then produce SARS-CoV-2-specific antibodies. Here, we review published data linking HLA genetic variation or polymorphisms with differences in SARS-CoV-2-specific antibody responses. While there is evidence that heterogeneity in antibody response might be related to HLA variation, there are conflicting findings due in part to differences in study designs. We provide insight into why more research is needed in this area. Elucidating the genetic basis of variability in the SARS-CoV-2 immune response will help to optimize diagnostic tools and lead to the development of new vaccines and therapeutics against SARS-CoV-2 and other infectious diseases.
Keywords: COVID-19; HLA; MHC; SARS-CoV-2; antibody; genomics; immunoglobulin; polymorphism.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10143129/bin/viruses-15-00906-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10143129/bin/viruses-15-00906-g002.gif)
Similar articles
-
HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection.Curr Opin Immunol. 2022 Jun;76:102178. doi: 10.1016/j.coi.2022.102178. Epub 2022 Mar 25. Curr Opin Immunol. 2022. PMID: 35462277 Free PMC article. Review.
-
Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides.J Hum Genet. 2022 Jul;67(7):411-419. doi: 10.1038/s10038-022-01013-4. Epub 2022 Feb 2. J Hum Genet. 2022. PMID: 35110673 Free PMC article.
-
The HLA-II immunopeptidome of SARS-CoV-2.Cell Rep. 2024 Jan 23;43(1):113596. doi: 10.1016/j.celrep.2023.113596. Epub 2023 Dec 20. Cell Rep. 2024. PMID: 38117652 Free PMC article.
-
HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease.Hum Immunol. 2023 Apr;84(4):263-271. doi: 10.1016/j.humimm.2023.02.002. Epub 2023 Feb 13. Hum Immunol. 2023. PMID: 36822912 Free PMC article.
-
HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.Virus Genes. 1994 Jul;8(3):249-70. doi: 10.1007/BF01704519. Virus Genes. 1994. PMID: 7975271 Review.
Cited by
-
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.PLoS One. 2024 Jul 29;19(7):e0303113. doi: 10.1371/journal.pone.0303113. eCollection 2024. PLoS One. 2024. PMID: 39074077 Free PMC article.
-
Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response.Commun Med (Lond). 2024 Apr 4;4(1):63. doi: 10.1038/s43856-024-00490-2. Commun Med (Lond). 2024. PMID: 38575714 Free PMC article.
-
Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241239202. doi: 10.1177/03946320241239202. Int J Immunopathol Pharmacol. 2024. PMID: 38494849 Free PMC article.
-
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.Front Immunol. 2024 Feb 16;15:1325387. doi: 10.3389/fimmu.2024.1325387. eCollection 2024. Front Immunol. 2024. PMID: 38469296 Free PMC article.
-
Individual Immune Response to SARS-CoV-2 Infection-The Role of Seasonal Coronaviruses and Human Leukocyte Antigen.Biology (Basel). 2023 Sep 28;12(10):1293. doi: 10.3390/biology12101293. Biology (Basel). 2023. PMID: 37887003 Free PMC article.
References
-
- Bennett T.D., Moffitt R.A., Hajagos J.G., Amor B., Anand A., Bissell M.M., Bradwell K.R., Bremer C., Byrd J.B., Denham A., et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data from the US National COVID Cohort Collaborative. JAMA Netw. Open. 2021;4:e2116901. doi: 10.1001/jamanetworkopen.2021.16901. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous